Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Environmental exposures have been postulated to affect the pathogenesis of many human diseases including blood cancers and predisposition conditions such as clonal hematopoiesis (CH). There are few systematic studies that have determined the magnitude of CH in well-defined cohorts of environmental exposures. We conducted deep sequencing analysis of 988 World Trade Center (WTC) responders (firefighters and emergency medical service) exposed to high levels of aerosolized dust, gases, and potential carcinogens associated with the World Trade Center (WTC) disaster to determine the prevalence of CH and the association between CH and leukemia. First, the CH prevalence among WTC-exposed responders was compared to that of two comparison cohorts: non-WTC-exposed firefighters (n=255) and non-WTC-exposed controls (n=195; individuals from the general population). We observed a significantly higher prevalence of CH among WTC-exposed responders (14%) versus non-WTC-exposed firefighters (7%, odds ratio (OR)=3.38; 95% CI 1.90-6.34) and non-WTC-exposed controls (general population; 7%, OR=3.57; 95% CI 1.94-7.01) after controlling for age, race, and sex. Interestingly, we did not observe an increased CH burden among non-WTC-exposed firefighters compared to controls from the general population, contrary to the anticipated increase due to occupational exposure to toxic smoke.

Even though DNMT3A and TET2 were the two most common mutated genes, the subsequent spectrum of mutations was distinct in younger WTC-exposed responders (age < 60) and included APC (6.6%), KMT2D(4.8%), ATM (4.8%), PIK3CA (4.2%) CREBBP (3.0%), BRCA2 (2.4%), ERBB4 (2.4%), and ARID1A (2.4%). Additionally, the risk of developing leukemia was elevated (3.7% vs 0.6%; OR, 5.73; 95% CI, 1.24-26.21) in WTC-exposed responders with CH compared to those without CH. Moreover, CH in younger responders was characterized by a higher variant allele frequency (Median VAF of 28% vs 13%) with 70% of the mutations being missense mutations. Analysis of overall mutational signatures in WTC-exposed responders demonstrated an enrichment of aging-related (Signature 1A) and defective homologous-recombination-based repair or BRCA1/BRCA2 mutation-associated signatures in younger WTC-exposed responders. We also observed increased levels of neutrophils, monocytes, and red cell width (RDW) in WTC-exposed responders with CH compared to those without CH, suggestive of elevated inflammation.

We created an in vivo model mimicking an 8-hour responder work-shift at the WTC site for responders by administering a single dose of WTC-particulate matter (WTC-PM; chemically characterized matter obtained from Ground Zero) to mice via oropharyngeal instillation. We found that administration of WTC-PM led to impaired hematopoietic stem cell (HSC) function in vivo. We utilized a non-conditioned Tet2^+/- bone marrow transplantation-based model of CH and found that WTC-PM exposure accelerated the growth of the mutant clones and increased the expression of IL-1 receptor accessory protein (IL1RAP), a sensor and mediator of inflammatory signals, on Tet2^+/- hematopoietic stem-progenitor cells (HSPCs). Heterozygous deletion of Il1rap significantly decreased the expansion of Tet2-mediated CH clones after WTC-PM exposure in vivo. Strikingly, the previously reported resistance to inflammation-mediated toxicity exhibited by Tet2-mutant cells was lost in Il1rap deficient Tet2-mutant cells.

Our study demonstrates a novel spectrum of CH mutations in younger, environmentally exposed responders. It shows an increased risk of developing leukemia, increased inflammation, and identifies IL1RAP as a mediator of CH progression and a potential therapeutic target in this context. Our study reveals associations between environmental exposures, hematopoietic stem cell clonal dynamics and somatic blood mutations using a unique cohort with well annotated exposure and clinical histories.

Bender:Neogenomics: Current Employment. Landgren:Adaptive: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Theradex: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees. Shastri:Gilead, Rigel, Kymera: Consultancy; NACE & PeerView: Honoraria; Jassen: Consultancy; Kymera: Research Funding; Ryvu therapeutics: Research Funding; Geron: Speakers Bureau. Savona:Incyte: Other: Grants or Contracts from entity; MDSF Foundation BOD: Membership on an entity's Board of Directors or advisory committees; Karyopharm, Ryvu, Empath Biosciences: Current equity holder in publicly-traded company; Boehringer, Empath Biosciences: Patents & Royalties; Astex: Other: Grants or Contracts from entity; Abbvie, BMS, CTI, Forma, Geron, GSK, Rigel, Taiho, and Treadwell: Consultancy. Steidl:Stelexis: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Pieris Pharmaceuticals: Consultancy; Vor Biopharma: Consultancy; Trillium Therapeutics: Consultancy; Novartis: Consultancy, Research Funding; Roche: Consultancy; Pfizer: Consultancy; Aileron Therapeutics: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Research Funding; Bayer Healthcare: Consultancy, Research Funding; Celgene: Consultancy. Verma:Calico: Membership on an entity's Board of Directors or advisory committees; Halia: Research Funding; Curis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bioconvergent health: Current equity holder in private company; Bristol Myers Squib: Research Funding; Prelude: Research Funding; Clinstreet: Current equity holder in private company; Stelexis: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.